Evidence map›Paper›PMID 28835406›Full record

ArticleNeurology2017

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Heinz Wiendl, Dennis Bourdette, Olga Ciccarelli

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Pulsed immune reconstitution therapy in multiple sclerosis.Therapeutic advances in neurological disorders · 2019
    Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Heinz WiendlFrom the Department of Neurology (H.W.), University of Muenster, Germany; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neuroinflammation (O.C.), UCL Institute of Neurology, University College London, UK. heinz.wiendl@ukmuenster.de.
Dennis BourdetteFrom the Department of Neurology (H.W.), University of Muenster, Germany; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neuroinflammation (O.C.), UCL Institute of Neurology, University College London, UK.
Olga CiccarelliFrom the Department of Neurology (H.W.), University of Muenster, Germany; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neuroinflammation (O.C.), UCL Institute of Neurology, University College London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple SclerosisAlemtuzumabAntibodies, Monoclonal, HumanizedHumansAlemtuzumabAntibodies, Monoclonal, Humanized

Identifiers

PMID28835406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.